PURPOSE: To evaluate the incidence of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in an initial 21-core extended biopsy scheme and to determine the prostate cancer detection rate in the repeated biopsy. METHODS: Between 2002 and 2008, 2,006 patients underwent a first 21-core extended biopsy scheme. Incidences of cancer, ASAP and HGPIN were studied. Cancer detection rate in the repeated 21-core extended biopsy for ASAP and HGPIN was reported and compared with those obtained on repeated biopsy for clinico-biological indications. RESULTS: Incidences of HGPIN and ASAP were 1.7 and 1.1%, respectively. The 6-core and 12-core biopsy schemes detecting HGPIN would have missed the diagnosis of cancer in 10 and 3.6% of cases, compared to a 21-core biopsy protocol, respectively. The cancer detection rate on repeated biopsy for HGPIN was 19% and not significantly different compared with the detection rate on repeated biopsy for clinico-biological indications (16.8%, p = 0.77). Seven prostate cancers were found among the 17 re-biopsies for ASAP revealing a detection rate of 41.2% (p = 0.01). All detected cancers were organ confined. No clinico-pathological data were independent predictor of cancer on repeated biopsy. CONCLUSION: Our report demonstrates the different risk profiles for HGPIN and ASAP in a 21-core extended biopsy scheme. The presence of HGPIN does not imply a higher risk for cancer detection at immediate re-biopsy compared to other patients for whom repeated biopsies were indicated for increasing or persistently increased PSA levels. Repeated biopsy is warranted when ASAP is diagnosed because of a high risk of prostate cancer.
PURPOSE: To evaluate the incidence of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in an initial 21-core extended biopsy scheme and to determine the prostate cancer detection rate in the repeated biopsy. METHODS: Between 2002 and 2008, 2,006 patients underwent a first 21-core extended biopsy scheme. Incidences of cancer, ASAP and HGPIN were studied. Cancer detection rate in the repeated 21-core extended biopsy for ASAP and HGPIN was reported and compared with those obtained on repeated biopsy for clinico-biological indications. RESULTS: Incidences of HGPIN and ASAP were 1.7 and 1.1%, respectively. The 6-core and 12-core biopsy schemes detecting HGPIN would have missed the diagnosis of cancer in 10 and 3.6% of cases, compared to a 21-core biopsy protocol, respectively. The cancer detection rate on repeated biopsy for HGPIN was 19% and not significantly different compared with the detection rate on repeated biopsy for clinico-biological indications (16.8%, p = 0.77). Seven prostate cancers were found among the 17 re-biopsies for ASAP revealing a detection rate of 41.2% (p = 0.01). All detected cancers were organ confined. No clinico-pathological data were independent predictor of cancer on repeated biopsy. CONCLUSION: Our report demonstrates the different risk profiles for HGPIN and ASAP in a 21-core extended biopsy scheme. The presence of HGPIN does not imply a higher risk for cancer detection at immediate re-biopsy compared to other patients for whom repeated biopsies were indicated for increasing or persistently increased PSA levels. Repeated biopsy is warranted when ASAP is diagnosed because of a high risk of prostate cancer.
Authors: Courtenay K Moore; Shridevi Karikehalli; Tipu Nazeer; Hugh A G Fisher; Ronald P Kaufman; Badar M Mian Journal: J Urol Date: 2005-01 Impact factor: 7.450
Authors: Rodolfo Montironi; Vincenzo Scattoni; Roberta Mazzucchelli; Antonio Lopez-Beltran; David G Bostwick; Francesco Montorsi Journal: Eur Urol Date: 2006-08-10 Impact factor: 20.096
Authors: William A Sterling; Joseph Weiner; David Schreiber; Komal Mehta; Jeffrey P Weiss Journal: Int Urol Nephrol Date: 2016-08-31 Impact factor: 2.370
Authors: A Leone; B Gershman; K Rotker; C Butler; J Fantasia; A Miller; A Afiadata; A Amin; A Zhou; Z Jiang; T Sebo; A Mega; S Schiff; G Pareek; D Golijanin; J Yates; R J Karnes; J Renzulli Journal: Prostate Cancer Prostatic Dis Date: 2015-11-17 Impact factor: 5.554
Authors: Leslie A Ynalvez; Christopher D Kosarek; Preston S Kerr; Ali M Mahmoud; Eduardo J Eyzaguirre; Eduardo Orihuela; Joseph N Sonstein; Stephen B Williams Journal: Int Urol Nephrol Date: 2017-10-24 Impact factor: 2.370
Authors: Renato Caretta Chambó; Fábio Hissachi Tsuji; Flávio de Oliveira Lima; Hamilto Akihissa Yamamoto; Carlos Márcio Nóbrega de Jesus Journal: Korean J Urol Date: 2014-11-04
Authors: Andrew Leone; Katherine Rotker; Christi Butler; Anthony Mega; Jianhong Li; Ali Amin; Stephen F Schiff; Gyan Pareek; Dragan Golijanin; Joseph F Renzulli Journal: Prostate Cancer Date: 2015-09-14